#Japan - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 

{By Norbert Kenntner, Berlin - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=1062838}

A wild Northern Goshawk in Hokkaido Region.

Source: WOAH, https://wahis.woah.org/#/in-review/6909

____

#Japan - High pathogenicity avian #influenza viruses (#poultry) (Inf. with) - Immediate notification

{ob1-Shiraoi-Town} On 21 October 2025, a Livestock Hygiene Service Centre (LHSC) in Hokkaido Prefecture received a notification from a domestic layer farm regarding an increase in bird mortality. Samples were collected from birds on the farm by LHSC officers and tested positive for influenza A virus using a viral antigen rapid test. On 22 October, the LHSC conducted RT-PCR and rRT-PCR tests and confirmed that the virus is of high pathogenicity. Movement and shipment restriction have been imposed on farms within a radius of 3 km and 10 km of the affected farm, respectively. Stamping-out and relevant control measures, including disinfection, are ongoing. The National Institute of Animal Health (NIAH) is sequencing the virus genome and will identify the subtype.

Source: WOAH, https://wahis.woah.org/#/in-review/6911

____

#Slovakia - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

 

Establishment registered for the direct supply of small quantities of animal products from the farm to the consumer: - 150 pcs Gallus gallus (22 dead) - 26 pcs geese (5 dead) - 21 pcs ducks (no clinical signs) Sudden deaths, haemorrhagies of the inner organs (intestines, spleen, lungs). Depopulation is ongoing.

Source: WOAH, https://wahis.woah.org/#/in-review/6916

____

Cross-Species #Transmission #Risks of a #Quail-Origin #H7N9 #Influenza Virus from #China Between Avian and #Mammalian Hosts

 

Abstract

The H7N9 influenza viruses, which are capable of causing severe respiratory syndrome in humans, were first discovered to infect humans in 2013 and continue to pose a persistent public health threat. Quail has been proposed as a potential intermediate host that may facilitate the emergence of novel reassorted influenza A viruses with the capacity to infect humans across species barriers; however, information on the biological characterization of quail H7N9 remains limited. In this study, we isolated and identified an avian H7N9 influenza virus from quails, designated as A/quail/Hebei/CH06-07/2018 (H7N9) and abbreviated as CH06-07, in Hebei, China. Phylogenetic analyses revealed that both the HA gene and the NA gene of CH06-07 were clustered in the Eurasian lineage. Furthermore, CH06-07 exhibited binding affinity for both α2,3-linked and α2,6-linked sialic acid receptors and demonstrated high pathogenicity in both quails and mice. Notably, transmission studies revealed that CH06-07 not only exhibited efficient inter-quail transmission and inter-guinea pig transmission but also demonstrated effective cross-species transmission. Importantly, infected quails and guinea pigs generated significant quantities of viral aerosols (≥18,998 ± 1672 copies per liter of air at 3 days post-infection), and infectious viruses were successfully recovered from environmental aerosols. These findings highlight the necessity for continuous surveillance of the prevalence of quail-origin H7N9 influenza A viruses in poultry populations due to their potential threat to human health.

Source: Viruses, https://www.mdpi.com/1999-4915/17/10/1402

____

#Italy, #WNV & #USUV Integrated #Surveillance - Weekly Bulletin No. 14, 15 Ocotber 2025 (ISS, edited)

 

{Summary}

-- New human cases of West Nile Virus infection continue to be reported albeit with reduced intensity. 

-- During current epidemiological week (from 9 to 15 October 2025) 26 new confirmed cases have been reported. 

-- The total number of cases so far is 767 (they were 740 last week), of these: 

- 366 were West Nile Neuroinvasive Disease (WNND): 17 in Piedmont, 56 Lombardy, 34 Veneto, 4 Friuli-Venezia Giulia, 1 Liguria, 32 Emilia-Romagna, 10 Tuscany, 1 Marche, 86 Latium, 2 Molise, 83 Campania, 2 Apulia, 2 Basilicata, 5 Calabria, 3 Sicily, 28 Sardinia, 

- 57 were asymptomatic cases among blood donors, 

- 333 were West Nile Fever cases (of which 1 imported from Kenya, 1 from Egypt and 1 from Maldive), 

- 3 asymptomatic cases, 

- eight unspecified cases. 

-- Among confirmed cases, 69 fatalities have been reported: 7 in Piedmont, 9 Lombardy, 2 Emilia-Romagna, 18 Latium, 29 Campania, 2 Calabria, 1 Sicily, 1 Sardinia. 

-- The case-fatality rate in WNND cases stands at 18.8% (in 2018 it was 20%, in 2024 it was 14%). 

-- So far this season, 10 cases of Usutu virus infection have been recorded: 2 in Piedmont, 3 Lombardy, 2 Veneto, 3 Latium.

(...)

Source: High Institute of Health, https://www.epicentro.iss.it/westnile/bollettino/Bollettino_WND_2025_14.pdf

____

#Cambodia notified two additional #human cases of infection with #influenza #H5N1, #Bangladesh one case of #H5, #China four cases of #H9N2 (HK CHP, Nov. 21 '25)

{Excerpt}

This Week:

[Date of report - Country - Province / Region District / City - Sex - Age - Condition at time of reporting  - Subtype of virus]

1) .../10/2025 - Cambodia - Takeo Province - F - 14 - Hospitalised - H5N1 

2) 16/10/2025 - Cambodia - Kampong Speu Province - F - 3 - Under intensive care - H5N1

(...)

[Place of occurrence - No. of cases  (No. of deaths) - Details]

-- Bangladesh - 1(0) 

- Avian influenza A(H5): 

1) Sylhet Division: A boy with onset on July 27, 2025. 

-- Chinese Mainland - 4(0) 

- Avian influenza A(H9N2): 

- Guangdong Province: 

1) An individual with onset in February 2025. The case was retrospectively reported. 

- Guangxi Zhuang Autonomous Region: 

2, 3) Two individuals with onset in February 2025. Both cases were retrospectively reported.  

- Tianjin Municipality: 

4) An individual with onset in February 2025. The case was retrospectively reported. 

-- Mexico - 1(0) 

- Avian influenza A(H5): 

1) Mexico City: A 23-year-old woman with onset on September 14, 2025. 

(...)

Source: Centre for Health Protection, Hong Kong PRC SAR, https://www.chp.gov.hk/files/pdf/2025_avian_influenza_report_vol21_wk42.pdf

____

Spatial #Variation of #SARS-CoV-2 #Exposure in Urban #Rodents from the Metropolitan Area of Buenos Aires, #Argentina: Implications for Public Health in Latin American Cities

 

Abstract

Background: 

The COVID-19 pandemic, driven by the SARS-CoV-2 virus, has become an unprecedented global public health challenge. Comprehensive investigation of the virus transmission dynamics requires exploration of all potential routes, including the role of animal reservoirs. This study aimed to assess the presence of SARS-CoV-2 RNA and antibodies in urban rodents captured within two landscape units (low-income neighborhoods and green spaces) in the metropolitan area of Buenos Aires (MABA), Argentina.

Methods: 

Between July 2020 and September 2022, 125 synanthropic rodents (68 Rattus norvegicus, 22 R. rattus, and 35 Mus musculus) from seven low-income neighborhoods and seven green spaces in the MABA were captured and examined for SARS-CoV-2 exposure and infection by indirect immunofluorescence serology and RT-qPCR, targeting the N, E, and ORF1ab genes.

Results: 

Two M. musculus and six R. norvegicus from five different low-income neighborhoods tested positive for SARS-CoV-2 antibodies. No rodent with positive serology was detected in green spaces. All rodents tested negative for SARS-CoV-2 RNA when analyzed by RT-qPCR.

Conclusion: 

The results of this study provide valuable insights into the ecological dynamics of SARS-CoV-2 in synanthropic rodents in two landscape units within a Latin American city, with seropositive rodents detected in low-income neighborhoods, suggesting a possible increased exposure risk in these settings. This information is critical for developing management strategies for potentially zoonotic viruses and underscores the importance of continued surveillance of SARS-CoV-2 in rodents as part of an integrated One Health approach.

Source: Vector-Borne and Zoonotic Diseases, https://www.liebertpub.com/doi/abs/10.1177/15303667251389403

____

#UK - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

{England} 300k laying hen premises. Samples were taken and were tested positive for HPAI H5N1. Clinical signs were presented prior to testing.

Source: WOAH, https://wahis.woah.org/#/in-review/6907

____

#Evolution of #antibody cross-reactivity to #influenza #H5N1 #neuraminidase from an N2-specific germline

 

Highlights

• Human antibody HB420 cross-reacts with neuraminidases from H3N2 and H5N1

• HB420 engages the neuraminidase active site via a single Asp residue

• Germline HB420 is N2 specific but gains reactivity to N1 through somatic mutation

• HB420 provides in vivo protection against both H3N2 and H5N1

Summary

The ongoing spread of highly pathogenic avian influenza H5N1 clade 2.3.4.4b virus in animals and its occasional spillover to humans have raised concerns about a potential H5N1 pandemic. Although recent studies have shown that pre-existing human antibodies can recognize H5N1 neuraminidase, the molecular basis of how this cross-reactivity develops remains poorly understood. In this study, we used a phage display antibody library derived from 245 healthy donors to isolate an antibody, HB420, that cross-reacts with neuraminidases of human H3N2 and avian H5N1 clade 2.3.4.4b viruses and confers protection in vivo. Cryogenic electron microscopy analysis reveals that HB420 targets the neuraminidase active site by mimicking sialic acid binding through a single Asp residue. Furthermore, the inferred germline of HB420 is N2 specific but acquires cross-reactivity to H5N1 neuraminidase through somatic hypermutation. Overall, our findings provide insights into how neuraminidase antibody evolves breadth, which has important implications for the development of broadly protective influenza vaccines.

Source: Cell Host & Microbe, https://www.sciencedirect.com/science/article/pii/S1931312825003816?via%3Dihub

____

#WHO occupied #Palestinian Territory 60 Day #Ceasefire #Plan for #Gaza, October 2025 (edited)

 

PURPOSE AND SCOPE 

-- With the initiation of the first phase of the ceasefire, humanitarian needs remain dire. 

-- In the current situation, it is crucial to scale up humanitarian aid in a coordinated manner while ensuring the start of early recovery and reconstruction. 

-- This document summarizes WHO’s key planning assumptions, strategic priorities and selected activities. 

-- The activities fall within the scope of the overall 2025 WHO operational response and early recovery plan for the occupied Palestinian territory and the One-UN multi-sectoral Gaza Ceasefire Humanitarian Response Plan Summary 60 days (13 October 2025).

ASSUMPTIONS 

-- This plan is developed under the following assumptions:  

- Continuation of ceasefire and improvement of the law-and-order situation.

- Improved access for UN with access/registration issues for INGOs remaining.

- Gradual emergence of a clear and functional governance structure. 

- Improved flexibility of entry of medical supplies and equipment, including dual use items. 

- Free movement in Gaza Strip Zone 1.

- Sustained opening of the Rafah Crossing and other corridors for persons, including medical evacuation and adequate numbers of medical evacuation offers from receiving countries.

- Public health risks largely in line with WHO’s 10th Public Health Situation Analysis for Gaza (Sept 2025 – ceasefire update ongoing). 

STRATEGIC PRIORITIES AND KEY ACTIVITIES 

-- WHO will scale up the provision of humanitarian aid and initiation of early recovery efforts, in collaboration with partners and stakeholders. 

A. Maintain and expand life-saving essential health services

- Provide essential medicines, medical supplies and equipment for primary and secondary health services (including Reproductive Maternal, Newborn, Child and Adolescent Health; Nutrition; Noncommunicable Disease; Trauma) ensuring appropriate standards in line with the WHO Priority Medicines List for Gaza. 

- Scale up the processing, clearance and entry of medical supplies and equipment to the Gaza Strip safely for WHO and partner organizations who require support.

- Scale-up of medical evacuations up to 50 patients per day plus companions, in line with the previous ceasef ire (currently over 15 000 patients are on the priority list).

- Re-establish and support utilities and support services at hospital level, e.g. oxygen plants, electricity/fuel and generators, mobile storage units. 

- Support the medical referral system, including spare parts for ambulances, ICU units for special transfers,  and coordination between facilities. 

- Scale up of rehabilitation services at all levels of health care, including limb reconstruction services and provision of assistive devices.

- Scale up of mental health and psychosocial support services at all levels of health care, up to specialized clinical care.

- Continue and expand WHO’s existing full support to 3 field hospitals.

- Intensify technical support to health service delivery across the health sector through assessments, monitoring, and capacity building.

- Ensure preparedness and health facility readiness for the possibility of a new escalation. 

B. Public health intelligence, early warning, and prevention and control of communicable disease

- Expansion and strengthening of surveillance for communicable diseases through the provision of surveillance equipment, expansion of Early Warning Alert and Response System, introducing linkages with laboratory and WASH data, and capacity building for Rapid Response Teams.

- Re-establish the Gaza Central Public Health Building, including rehabilitation of laboratory infrastructure, provision of essential equipment, and staffing capacity.

- Provide hospital laboratories with essential diagnostic and antimicrobial resistance equipment and testing supplies.

- Support the availability of safe blood, including entry of blood into the Gaza Strip, restarting local donations, and safety testing.

- Implement the catch-up campaign for immunization to target 40 000 children under the age of 3 that are missing doses or zero-dose for immunizations.

- Provide infection prevention and control support including establishment of isolation capacity, supplies, and capacity building. 

- Continue water quality testing and support to WASH in health facilities.

- Undertake modelling exercises to estimate excess mortality, in collaboration with academic and local partners. 

C. Health emergency coordination

- Health Cluster coordination and support to over 88 health partners to scale up humanitarian support to essential health services for the population of Gaza.

- Emergency Medical Teams (EMTs) scale up from approximately 30 deployed teams to approximately 40 deployed teams to support Gaza’s health system.

- Strengthen the Humanitarian-Development-Peace Nexus through the establishment and leadership of a dedicated technical working group under the Health Cluster to enable coordination between humanitarian and recovery efforts in health.

- Ensure Prevention of Sexual Exploitation and Abuse (PSEA) technical advice and support to partners.

- Coordinate the European Gaza Hospital (EGH) committee under the Health Cluster to operationalize the resumption of services (phase one to restore minimum functionality – two weeks, phase two towards partial functionality – two months). 

D. Early recovery, rehabilitation and reconstruction 

-- WHO will focus its early recovery planning around the priorities and activities outlined below. 

-- It is important to note that implementation of these activities will extend beyond the initial 60-day period. However, WHO will require initial resources to prepare, plan and launch the early recovery efforts. 

• Primary health care (PHC) services

- Rehabilitation of 10 primary health care centres (Level III and IV).

- Rehabilitation and restoration/expansion of 3 primary health care services with pre-fabricated structures, equipment and medical supplies, and operational costs. 

• Secondary/tertiary health services

- Two field-hospitals - expand bed capacities for the hospitals (e.g. Al Wafaa Rehabilitation Hospital, Al Shifa Hospital).

- Two pre-fabricated modular clinics - ensure continuity of services during the reconstruction of hospitals.

- Early rehabilitation/expansion of 3 selected general hospitals (e.g. Al Shifa Hospital in Gaza City; Al Aqsa Hospital in Middle Area; EGH Hospital in Khan Younis or Indonesian Hospital in North Gaza). 

• Support the coordination of health sector recovery and recovery planning

- Engage with emerging governance structure, Interim Rapid Damage and Needs Assessment (IRNDA)  up-date and plan/prepare for the implementation of early recovery priorities. 

- Health system design: Support the development of a strategic framework for rebuilding a resilient, equitable, and integrated health facility network across the Gaza Strip (rationalized, health needs-based, and cost-effective reconstruction). 

• Facilitating early recovery

- Strengthen and increase the number of health workforce: with salary/incentive payments and deployment of specialized EMTs with surge and training capacities (physical rehabilitation and noncommunicable diseases advanced services).

- Supply chain management, forecasting, warehousing facilities (2 warehouses for medical supplies, decentralized North/South).

REQUIREMENT 

-- Pillar

{A}. Maintain and expand life-saving essential health services: USD 19,500,000

{B}. Public health intelligence, early warning, and prevention and control of communicable disease:  5,500,000

{C}. Health emergency coordination (including Health Cluster and EMT coordination): 1,000,000

{D}. Early recovery, rehabilitation and reconstruction: 19,000,000

{Total} 45,000,000 

Note: Operations costs are integrated in pillars A-D. 

___

Source: World Health Organization, https://www.who.int/publications/m/item/60-day-ceasefire-plan-for-gaza

____

The Virgin and Child Reading, Jan van Eyck (1433)

 

Public Domain.

Source: WikiArt, https://www.wikiart.org/en/jan-van-eyck/madonna-from-the-inn-s-hall-1433

____

Host #Immunomodulatory Interventions in Severe #Influenza

 

Abstract

Currently, no immunomodulatory agents have been conclusively shown to benefit severe influenza. The World Health Organization conditionally advises against the use of systemic corticosteroids, macrolides, plasma therapy, mechanistic target of rapamycin inhibitors, and nonsteroidal anti-inflammatory drugs for such patients. High-dose systemic corticosteroids may increase mortality and morbidity in severe influenza; the potential of low-dose corticosteroids merits further study given survival benefits in patients with severe coronavirus disease 2019 (COVID-19). Passive immunotherapy using convalescent plasma or intravenous immunoglobulin (IVIG) from healthy donors has not proven effective, suggesting that future research should focus on hyperimmune plasma or IVIG from recent infections. An open-label randomized controlled trial (RCT) found that a triple combination of oseltamivir, clarithromycin, and naproxen improved outcomes in severe influenza. One RCT has indicated that sirolimus with corticosteroids can expedite liberation from mechanical ventilation and reduce viral load, warranting larger trials of sirolimus alone. In contrast, adding macrolides or nitazoxanide has not consistently improved clinical outcomes. Promising evidence exists for anti-C5a antibodies in COVID-19, while case reports hint that intravenous N-acetylcysteine may benefit severe influenza pneumonia. Observational data on statins remain conflicting. Further studies on COX-2 inhibitors in combination with antivirals and other immunomodulators are needed. Mycophenolic acid, pamidronate, and peroxisome proliferator-activated receptor gamma agonists are low priorities due to toxicity concerns. Research into human mesenchymal stromal cells and herbal medicine remains inconclusive. Overall, these findings support large-scale trials to validate promising results and address limitations in small studies. Treatment of severe influenza requires a multidisciplinary approach that integrates antiviral and immunomodulatory strategies. Clarifying these roles may enhance patient outcomes.

Source: Journal of Infectious Diseases, https://academic.oup.com/jid/article/232/Supplement_3/S262/8287912

____

Serological #Evidence of Exposure to Eurasian-Lineage HPAI #H5N1 Clade 2.3.4.4b in Wild #Mammals in #Ohio, #USA, 2024–2025

 

Abstract

The Goose/Guandong lineage of highly pathogenic avian influenza virus [A/Goose/Guangdong/1/1996(H5N1)] is the progenitor of the currently circulating Eurasian-lineage highly pathogenic avian influenza H5N1 clade 2.3.4.4b and has been the most consequential highly pathogenic avian influenza lineage globally. Despite increased reports of infections, the extent of exposure and role of wild mammals in the ecology and transmission dynamics of the virus remains poorly understood. We surveyed wild mammals in Ohio, United States to investigate the potential spillover of highly pathogenic H5N1 avian influenza clade 2.3.4.4b. While no active infections—defined as positive results indicative of viral replication and potential propagation—were detected by swab-based molecular tests, serological assays revealed antibodies against multiple avian influenza virus antigens in raccoons and opossums. Specifically, antibodies to avian influenza virus nucleoprotein were detected in 54.9% (n = 61) of samples using enzyme-linked immunosorbent assay; antibodies to Eurasian-lineage highly pathogenic avian influenza H5 clade 2.3.4.4b and North American low pathogenic avian influenza H5 were detected in 43.2% (n = 48) and 22.5% (n = 25) of samples, respectively, using virus neutralization assays; and antibodies to avian influenza virus neuraminidase were detected in 44.1% (n = 49) of samples using enzyme-linked lectin assay. All seropositive animals were sampled at Ohio marshes with previously confirmed highly pathogenic avian influenza H5N1 detections in waterfowl. These findings suggest prior exposure of wild mammals to these viruses without mortality events. Wild mammals may play an intermediary role in the mammalian adaptation of avian influenza A viruses. Therefore, ongoing surveillance of wild mammals is crucial for assessing the risk to public health.

Source: Viruses, https://www.mdpi.com/1999-4915/17/10/1388

____

Active #Surveillance for Emerging #Influenza A Viruses – Findings from a #OneHealth Study in #Vietnam’s Live Bird #Markets

 

Highlights

-- We conducted surveillance for influenza A viruses at live bird markets in northern Vietnam.

-- Six different subtypes of influenza A virus were found co-circulating in the markets.

-- Notable genetic mutations were found across many genes.

-- These markets have great potential to generate new pandemic influenza A virus strains.

Abstract

Objectives

Live bird markets (LBMs) in Asia have often been the source of human infections with avian influenza virus (AIV).

Methods

From July 2021 to August 2023, we employed a One Health approach in conducting periodic surveillance for novel influenza A viruses in five LBMs in northern Vietnam. Specimens were studied with egg culture, molecular assays, Sanger sequencing, and next-generation sequencing.

Results

We studied a total of 688 human, avian, and bioaerosol specimens. Among these, 118 (17.2%) were found to have molecular evidence of AIVs. Next-generation sequencing of 92 isolates revealed multiple AIV subtypes, including H4N6 (n=1), H5N1 (n=3), H5N8 (n=6), H6N2 (n=3), H6N6 (n=18), and H9N2 (n=61) and mix infections (n=7). Our H5Nx sequences belonged to the Eurasian lineage clade 2.3.4.4b, while our H6N2 sequences were of group III, H6N6 of group II, and H9N2 of the BJ94-lineage clade 4.6.14.

Conclusions

The relatively high prevalence of AIV, particularly highly pathogenic H5N1 and H5N8 viruses, along with the subtype diversity, frequent co-infections and notable mutations, highlights the urgent need for continued monitoring and control of AIV in Vietnam’s poultry farms and LBMs.

Source: International Journal of Infectious Diseases, https://www.ijidonline.com/article/S1201-9712(25)00354-6/fulltext

____

Toddler in western #Cambodia becomes 16th #H5N1 bird #flu virus victim in 2025 (Antara)

 

{Excerpt}

Phnom Penh (ANTARA) - A 3-year-old girl from Kampong Speu Province, western Cambodia, has been confirmed to have contracted H5N1 bird flu, bringing the number of cases to 16 so far this year, the Cambodian Ministry of Health said in a statement on Thursday (16/10) evening local time.

Laboratory results from Cambodia's National Institute of Public Health on October 15 showed the girl tested positive for the H5N1 virus, the statement said.

The patient had symptoms of fever, diarrhea, cough, and abdominal pain, and is currently undergoing intensive care with a team of doctors, the statement added.

The girl is a resident of Chek Village, Basedth District.

Investigations found that chickens and ducks had contracted the disease and died at the girl's home and at her neighbor's about a week before she fell ill, the statement said.

(...)

Source: Antara, https://www.antaranews.com/berita/5181569/balita-di-kamboja-barat-jadi-korban-flu-burung-ke-16-pada-2025

____

History of Mass Transportation: The Henschel's Steam Locomotive No. 1 ''Drake'' (1848)

 

By Henschel & Sohn Cassel - https://orka.bibliothek.uni-kassel.de/viewer/image/1583329169073/11/#topDocAnchor, Public Domain, https://commons.wikimedia.org/w/index.php?curid=164351448

Source: Wikipedia, https://en.wikipedia.org/wiki/Henschel_%26_Son

____

#Coronavirus Disease Research #References (by AMEDEO, October 18 '25)

 

AJR Am J Roentgenol

1. LITTLE BP
   Imaging and Reporting of Post-COVID-19 Lung Abnormalities at CT: International Panel of Experts Provides Welcome Guidance.
   AJR Am J Roentgenol. 2025 Oct 15. doi: 10.2214/AJR.25.33999.
   PubMed        
   
   

   
   Infect Control Hosp Epidemiol

2. ELHAISSOUNI N, Arthur A, Prochaska EC, Colantuoni E, et al
   Association of pandemic precautions and Staphylococcus aureus in the NICU.
   Infect Control Hosp Epidemiol. 2025 Oct 13:1-3. doi: 10.1017/ice.2025.10319.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

3. OPPONG AE, Coelewij L, Hutchinson M, Carpenter B, et al
   Simple hyperinflammation scores predict mortality in hospitalised patients with COVID-19 and offer a personalised medicine approach to dexamethasone intervention.
   Int J Infect Dis. 2025 Oct 13:108119. doi: 10.1016/j.ijid.2025.108119.
   PubMed         Abstract available
   
   

   
   J Infect

4. TANG X, Ma T, Yao Z, Zhang L, et al
   The triumvirate of mutation bias, population dynamics, and natural selection in shaping SARS-CoV-2 intra-host variation.
   J Infect. 2025;91:106628.
   PubMed        
   
   

   
   J Med Virol

5. GAKLIK LTA, Carneiro BM
   Assessing Influenza and SARS-CoV-2 Coinfection in Brazil: A Comprehensive Study of Patient Outcomes From 2020 to 2023.
   J Med Virol. 2025;97:e70639.
   PubMed         Abstract available
   
   
6. PARRY RH, Shang Y, Sng JDJ, McMillan CLD, et al
   Vaccine-Induced and Hybrid Immunity Against SARS-CoV-2 Variants of Concern in Two Cohorts in Queensland, Australia (2021-2022).
   J Med Virol. 2025;97:e70642.
   PubMed         Abstract available
   
   
7. CHEN W, Li J, Bai S, Zhang A, et al
   Kinetics of IgA Subtypes and Cytokines in Respiratory Secretions Following Immunization With COVID-19 Mucosal Vaccine.
   J Med Virol. 2025;97:e70638.
   PubMed         Abstract available
   
   

   
   J Virol

8. DING S, Yang D, Ullah I, Niu L, et al
   Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants.
   J Virol. 2025 Oct 13:e0103425. doi: 10.1128/jvi.01034.
   PubMed         Abstract available
   
   
9. DADONAITE B, Harari S, Larsen BB, Kampman L, et al
   Spike mutations that affect the function and antigenicity of recent KP.3.1.1-like SARS-CoV-2 variants.
   J Virol. 2025 Oct 13:e0142325. doi: 10.1128/jvi.01423.
   PubMed         Abstract available
   
   
10. YU J, Sun Q, Zhu J, Cui Y, et al
    The integrin protein ITGbeta1 effectively suppresses porcine epidemic diarrhea virus replication through facilitating MDA5 oligomerization and subsequent activation of the type I interferon signaling pathway.
    J Virol. 2025 Oct 17:e0155325. doi: 10.1128/jvi.01553.
    PubMed         Abstract available
    
    

    
    JAMA

11. SAUGEL B, Meidert AS, Brunkhorst FM, Bischoff R, et al
    Individualized Perioperative Blood Pressure Management in Patients Undergoing Major Abdominal Surgery: The IMPROVE-multi Randomized Clinical Trial.
    JAMA. 2025 Oct 12:e2517235. doi: 10.1001/jama.2025.17235.
    PubMed         Abstract available
    
    

    
    Lancet

12. THE LANCET
    Health progress in a post-COVID-19 world.
    Lancet. 2025 Oct 12:S0140-6736(25)01947-6. doi: 10.1016/S0140-6736(25)01947.
    PubMed        
    
    
13. 
    Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01917-8. doi: 10.1016/S0140-6736(25)01917.
    PubMed         Abstract available
    
    
14. 
    Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01330-3. doi: 10.1016/S0140-6736(25)01330.
    PubMed         Abstract available
    
    
15. 
    Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Stud
    Lancet. 2025 Oct 12:S0140-6736(25)01637-X. doi: 10.1016/S0140-6736(25)01637.
    PubMed         Abstract available
    
    
16. REHM J, Assanangkornchai S, Hendershot CS, Franklin A, et al
    Alcohol use disorders.
    Lancet. 2025 Oct 9:S0140-6736(25)01496-5. doi: 10.1016/S0140-6736(25)01496.
    PubMed         Abstract available
    
    
17. RANDERATH W, Grote L, Stenlof K, Fietze I, et al
    Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial.
    Lancet. 2025 Oct 9:S0140-6736(25)01196-1. doi: 10.1016/S0140-6736(25)01196.
    PubMed         Abstract available
    
    
18. NDEMBI N, Mercy K, Folayan MO, Abdool Karim SS, et al
    Analysis of mpox in Angola conflates distinct timelines.
    Lancet. 2025;406:e29.
    PubMed        
    
    

    
    Lancet Infect Dis

19. SCHILLING WHK, Jittamala P, Wongnak P, Watson JA, et al
    Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Lancet Infect Dis. 2025 Oct 10:S1473-3099(25)00482.
    PubMed         Abstract available
    
    
20. HONG CM, Hung IFN
    Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment.
    Lancet Infect Dis. 2025 Oct 10:S1473-3099(25)00549.
    PubMed        

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, October 18 '25)

 

Antiviral Res

1. PATEL MC, Nguyen HT, Mishin VP, Pascua PNQ, et al
   Antiviral susceptibility monitoring: testing algorithm, methods, and findings for influenza season, 2023-2024.
   Antiviral Res. 2025 Oct 11:106299. doi: 10.1016/j.antiviral.2025.106299.
   PubMed         Abstract available
   
   
2. ZHU C, Wang Z, Pan Z, Mai X, et al
   DMBT1 promotes SARS-CoV-2 infection and its SRCR-derived peptide inhibits SARS-CoV-2 infection.
   Antiviral Res. 2025 Sep 3:106269. doi: 10.1016/j.antiviral.2025.106269.
   PubMed         Abstract available
   
   
3. TASHIMA R, Kuroda T, Nobori H, Miyagawa S, et al
   Ensitrelvir suppresses prolonged olfactory abnormalities derived from SARS-CoV-2 infection in hamsters.
   Antiviral Res. 2025 Sep 2:106270. doi: 10.1016/j.antiviral.2025.106270.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

4. WU LE, Wei JY, Lin ZH, Li HC, et al
   Clinical characteristics of children with idiopathic nephrotic syndrome infected with SARS-CoV-2: a single-center retrospective cohort study.
   BMC Pediatr. 2025;25:803.
   PubMed         Abstract available
   
   

   
   J Infect Dis

5. HENAUT M, Carbonneau J, Levade I, Boivin G, et al
   Fitness of SARS-CoV-2 Omicron Subvariants in Respiratory and Gastrointestinal Cell Lines as Determined by Reverse-Transcription Droplet Digital PCR and Whole-Genome Sequencing.
   J Infect Dis. 2025;232:e656-e660.
   PubMed         Abstract available
   
   
6. KITTIKRAISAK W, Mohanty S, Klungthong C, Macareo L, et al
   Antenatal Respiratory Syncytial Virus and Human Metapneumovirus Illness Rates Among Pregnant Women in Thailand and the Association Between Antenatal Respiratory Syncytial Virus and Perinatal Outcomes: A Prospective Cohort Study.
   J Infect Dis. 2025;232:e651-e655.
   PubMed         Abstract available
   
   
7. ATMAR RL, Lyke KE, Posavad CM, Deming ME, et al
   Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
   J Infect Dis. 2025 Apr 29:jiaf176. doi: 10.1093.
   PubMed         Abstract available
   
   
8. JIANG D, Hurst JH, Mohamed G, Kelly MS, et al
   Decreased Microbiota-Driven Tyrosine Metabolism Is Associated With Symptomatic COVID-19 in Children.
   J Infect Dis. 2025;232:796-805.
   PubMed         Abstract available
   
   
9. SAMANDARI T, Achola M, Hutter JN, Mboya G, et al
   Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults.
   J Infect Dis. 2025 Aug 2:jiaf398. doi: 10.1093.
   PubMed         Abstract available
   
   
10. BUI VL, Ragonnet R, Hughes AE, Shipman DS, et al
    Impact of Case Detection and Covid-19-Related Disruptions on Tuberculosis In Vietnam: A Modelling Analysis.
    J Infect Dis. 2025 Aug 7:jiaf406. doi: 10.1093.
    PubMed         Abstract available
    
    
11. WAITE AAC, Peto L, Gordon AC, Horby P, et al
    Platform Trials to Assess Therapeutics in Patients Hospitalized With Influenza.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
12. BRIGHT RA
    Optimizing Antiviral Stockpiles for Pandemic Response: A Strategic Framework.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
13. SHINDO N, Huvos A, Nguyen T
    Evolution of WHO Influenza Antiviral Stockpile: Rapid Access and Use in Low- and Middle-Income Countries for Pandemic Preparedness and Response.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
14. HAYDEN FG, Whitley RJ
    Introduction and Update: Advances in Influenza Therapeutics.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
15. LEE K, Pavia AT, Englund JA
    Improving Access to Influenza Testing and Treatment: Is It Time for Over-the-counter Oseltamivir?
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
16. TAKASHITA E, Wolfe CR, Jones JC
    Laboratory Methods for Monitoring Influenza Antiviral Resistance.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
17. DAMHORST GL, Lam WA
    Point-of-care and Home Use Influenza Diagnostics for Advancing Therapeutic and Public Health Strategies.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
18. ZAMBON M, Myles P, Sugaya N
    Use of Influenza Antivirals in Pandemic Response.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
19. BEIGEL JH, Oldach D
    Polyclonal and Monoclonal Antibodies for the Treatment and Prevention of Influenza.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
20. HASTINGS LE, Acosta EP, Kimberlin DW
    Influenza Antiviral Pharmacokinetic-Pharmacodynamic Relationships in Pregnancy, Infancy, and Early Childhood.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
21. KARAKONSTANTIS S, Lytras T, Keske S, Tsiodras S, et al
    The Care Continuum of Patients With Influenza in the Post-COVID-19 Era: A Position Paper.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
22. HELDMAN MR, Boeckh MJ, Ison MG
    Influenza Antivirals for Prevention and Treatment in Immunocompromised People.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
23. COWLING BJ, Lin Y, Ikematsu H
    Use of Influenza Antivirals to Prevent Transmission.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
24. PASCO R, Hayden FG, Meyers LA
    Modeling Influenza Antiviral Strategies: Reducing Burden and Preventing Resistance.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
25. LI J, Jin Y, Wang Y, Shang L, et al
    New Developments in Influenza Polymerase Inhibitors.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
26. UYEKI TM, Belser JA
    Antivirals for Novel Influenza A Virus Infections.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
27. HUI DSC, Chan KKP
    Host Immunomodulatory Interventions in Severe Influenza.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

28. JOUBBI S, Micheli A, Milazzo P, Ciano G, et al
    Enhancing antibody-antigen interaction prediction with atomic flexibility.
    PLoS Comput Biol. 2025;21:e1013576.
    PubMed         Abstract available
    
    
29. ERANTI P, Hegde M, Al Sium SM, Parra RG, et al
    Impact of the COVID-19 pandemic on computational biology early career researchers: A global retrospective study.
    PLoS Comput Biol. 2025;21:e1013554.
    PubMed         Abstract available
    
    
30. TORRAS-PEREZ M, Yoon IHR, Weeratunga P, Ho LP, et al
    Topology across scales on heterogeneous cell data.
    PLoS Comput Biol. 2025;21:e1013460.
    PubMed         Abstract available
    
    

    
    PLoS Med

31. KAWAMOTO A, Hashida M, Ishida K, Furihata K, et al
    Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study.
    PLoS Med. 2025;22:e1004499.
    PubMed         Abstract available
    
    

    
    PLoS One

32. RISNER M, Hu L, Stamoulis C
    Pre-pandemic mental health and brain characteristics predict adolescent stress and emotions during the COVID-19 pandemic.
    PLoS One. 2025;20:e0334028.
    PubMed         Abstract available
    
    
33. HADAYA J, Ebrahimian S, Cho NY, Kim S, et al
    Trends and outcomes of cardiac arrest and extracorporeal membrane oxygenation during the COVID-19 pandemic in the United States.
    PLoS One. 2025;20:e0334896.
    PubMed         Abstract available
    
    
34. MAGBOR P, Wang WZ, Gugan G, Olabode AS, et al
    Spatiotemporal structure of SARS-CoV-2 mutational frequencies in wastewater samples from Ontario.
    PLoS One. 2025;20:e0333945.
    PubMed         Abstract available
    
    
35. DUBUIS ME, Racine E, Vyskocil JM, Turgeon N, et al
    Correction: Ozone inactivation of airborne influenza and lack of resistance of respiratory syncytial virus to aerosolization and sampling processes.
    PLoS One. 2025;20:e0334842.
    PubMed         Abstract available
    
    
36. WAGELAAR EM, Hogeveen LS, Jonkman NH, Bakker A, et al
    Healthcare employees' perspectives on organizational communication about preventive mental health interventions: A focus group study.
    PLoS One. 2025;20:e0334716.
    PubMed         Abstract available
    
    
37. ELLEGAARD KM, Gunalan V, Sieber R, Baig SJ, et al
    SARS-CoV-2 sequencing artifacts associated with targeted PCR enrichment and read mapping.
    PLoS One. 2025;20:e0334009.
    PubMed         Abstract available
    
    
38. SHAKEEL I, Rashid HB, Ain QU, Inayat A, et al
    Prevalence and risk factors of Influenza Avian Virus in backyard pigeons, ducks, and chickens in Toba Tek Singh District, Pakistan.
    PLoS One. 2025;20:e0314186.
    PubMed         Abstract available
    
    
39. NAGRA G, Ezeugwu VE, Bostick GP, Branton E, et al
    Return-to-work for people living with long COVID: A scoping review of interventions and recommendations.
    PLoS One. 2025;20:e0321891.
    PubMed         Abstract available
    
    
40. MEJIA GOMEZ LA, Menendez D, Umscheid V, Gelman SA, et al
    Who gets sicker and why? Parents' perceptions of COVID-19 disparities and how they would explain them to their children.
    PLoS One. 2025;20:e0332140.
    PubMed         Abstract available
    
    
41. HOSSEN MT, Alam MSB, Islam MS, Montomoli E, et al
    Impact of the COVID-19 pandemic on the routine immunization system in Bangladesh.
    PLoS One. 2025;20:e0334503.
    PubMed         Abstract available
    
    
42. WENG PY, Li D, Liao ML, Chiang YC, et al
    Aging in rural communities: Engagement in indoor leisure activities and older adult health.
    PLoS One. 2025;20:e0334111.
    PubMed         Abstract available
    
    
43. GAO F, Wang D, Zuo L, Sun J, et al
    Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases.
    PLoS One. 2025;20:e0327297.
    PubMed         Abstract available
    
    
44. CHICOINE N, Griffin J
    The unreliability of estimated release dates in hospital drug shortage management: A case study of hospital pharmacy operations during the COVID-19 pandemic.
    PLoS One. 2025;20:e0328747.
    PubMed         Abstract available
    
    

    
    Vaccine

45. PIRES C
    Influenza vaccine hesitancy in the elderly: Where do we stand?
    Vaccine. 2025;66:127831.
    PubMed         Abstract available

Unexpected #Detection of Highly Pathogenic Avian #Influenza (HPAI) #H5N1 virus in #bovine #Semen

 

Abstract

Since March 2024, HPAI H5N1 virus has infected dairy cattle in the U.S., prompting concern about novel transmission routes. During an outbreak in California, HPAI H5N1 RNA was detected in an asymptomatic bull's semen. Although infectious virus was not isolated, questions remain about semen-associated transmission risks and biosecurity practices.

Competing Interest Statement

The authors have declared no competing interest.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.10.16.682947v1

____

#Iceland - #Influenza A #H5 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 

{[Common Raven] By Accipiter (R. Altenkamp, Berlin) - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=6806927}

___

Note 16/10/2025: The case reported in this event was confirmed to be H5 but was negative for N1 and N5. Therefore, it is assumed that a new serotype has been detected in the country.

The raven was found sick with a broken wing, emaciated and with diarrhea. It was euthanized.

Source: WOAH, https://wahis.woah.org/#/in-review/6868

____